fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Semaglutide

Form:

15 of 15 products shown

13 Limited Use · 2 not a benefit

Apo-Semaglutide Injection · DIN 02568020 · 0.68 mg/mL · injection solution - pre-filled pen 3mL Pk

Limited Use, Reason for Use code 667 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 667 required
Write on scriptReason for Use code 667 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 667
Reason for Use code 667 For the treatment of adult patients with type 2 diabetes when adequate glycemic control is not achieved on the maximum tolerated dose of metformin or where metformin is contraindicated or inappropriate. Semaglutide is not funded in combination with another glucagon-like peptide-1 receptor agonist (GLP-1 RA) or dipeptidyl peptidase-4 (DPP-4) inhibitor. Injectable semaglutide is not funded in combination with oral semaglutide. Coverage is only provided for one dosage format. Reimbursed dose: As per the product monograph Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Apo-Semaglutide Injection · DIN 02568020 Manufacturer: Apotex Inc.; listing date 2026-06-30 Health Canada: Marketed since 2026-05-14 · brand APO-SEMAGLUTIDE INJECTION · ATC A10BJ06 SEMAGLUTIDE · form Solution · route Subcutaneous · ingredients SEMAGLUTIDE 0.68 MG/ML · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Semaglutide Injection: Formulary list price $78.14 per unit (the source does not state the unit; exact figure $78.1410). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02568020)

Source record
DIN 02568020: Apo-Semaglutide Injection Raw flags: insOH=Y, sec12=Y, sec3=Y Item: 682006009; group id 759; item number 1864; lccId 00382; manufacturer id APX Source form: Inj Sol - Pref Pen 3mL Pk; strength: 0.68mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; diabetes medication flag Source prices (unrounded): $78.1410; ministry $78.1410 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02568020 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=107038
Interchangeable products
Ozempic · DIN 02540258 · $78.1410
Shortage status: active shortage (reported September 15, 2026, last updated September 17, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02568020
Shortage record checked October 6, 2026

Ozempic · DIN 02540258 · 0.68 mg/mL · injection solution - pre-filled pen 3mL Pk

Limited Use, Reason for Use code 667 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 667 required
Write on scriptReason for Use code 667 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 667
Reason for Use code 667 For the treatment of adult patients with type 2 diabetes when adequate glycemic control is not achieved on the maximum tolerated dose of metformin or where metformin is contraindicated or inappropriate. Semaglutide is not funded in combination with another glucagon-like peptide-1 receptor agonist (GLP-1 RA) or dipeptidyl peptidase-4 (DPP-4) inhibitor. Injectable semaglutide is not funded in combination with oral semaglutide. Coverage is only provided for one dosage format. Reimbursed dose: As per the product monograph Coverage limit: LU Authorization Period: Indefinite
Savings card: innoviCares lists Ozempic (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Ozempic · DIN 02540258 Manufacturer: Novo Nordisk Canada Inc; listing date 2024-01-31 Health Canada: Marketed since 2023-12-22 · brand OZEMPIC · ATC A10BJ06 SEMAGLUTIDE · form Solution · route Subcutaneous · ingredients SEMAGLUTIDE 0.68 MG/ML · company Novo nordisk canada inc · schedule Schedule d, Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02540258)

Source record
DIN 02540258: Ozempic Raw flags: insOH=Y, sec12=Y, sec3=Y Item: 682006009; group id 759; item number 1864; lccId 00382; manufacturer id NOO Source form: Inj Sol - Pref Pen 3mL Pk; strength: 0.68mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; diabetes medication flag Source prices (unrounded): $227.9400; ministry $78.1410 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02540258 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102895
Interchangeable products
Apo-Semaglutide Injection · DIN 02568020 · $78.1410
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02540258
Shortage record checked October 6, 2026

Semaglutide Injection · DIN 02567806 · 1.34 mg/mL · injection solution-pre-filled pen 1.5mL Pk

Limited Use, Reason for Use code 666 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 666 required
Write on scriptReason for Use code 666 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 666
Reason for Use code 666 For the treatment of adult patients with type 2 diabetes when adequate glycemic control is not achieved on the maximum tolerated dose of metformin or where metformin is contraindicated or inappropriate. Semaglutide is not funded in combination with another glucagon-like peptide-1 receptor agonist (GLP-1 RA) or dipeptidyl peptidase-4 (DPP-4) inhibitor. Injectable semaglutide is not funded in combination with oral semaglutide. Coverage is only provided for one dosage format. Reimbursed dose: As per the product monograph Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Semaglutide Injection · DIN 02567806 Manufacturer: Dr. Reddy's Laboratories Inc.; listing date 2026-06-30 Health Canada: Marketed since 2026-05-06 · brand SEMAGLUTIDE INJECTION · ATC A10BJ06 SEMAGLUTIDE · form Solution · route Subcutaneous · ingredients SEMAGLUTIDE 1.34 MG/ML · company Dr reddy's laboratories ltd · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Semaglutide Injection: Formulary list price $78.14 per unit (the source does not state the unit; exact figure $78.1410). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02567806)

Source record
DIN 02567806: Semaglutide Injection Raw flags: insOH=Y, sec12=Y, sec3=Y Item: 682006002; group id 760; item number 1865; lccId 00383; manufacturer id DRR Source form: Inj Sol-Pref Pen 1.5mL Pk; strength: 1.34mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; diabetes medication flag Source prices (unrounded): $78.1410; ministry $78.1410 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02567806 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=107018
Interchangeable products
Ozempic · DIN 02471477 · $78.1410
Shortage status: active shortage (reported July 20, 2026, last updated September 16, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02567806
Shortage record checked October 6, 2026

Apo-Semaglutide Injection · DIN 02568012 · 1.34 mg/mL · injection solution-pre-filled pen 3mL Pk

Limited Use, Reason for Use code 665 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 665 required
Write on scriptReason for Use code 665 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 665
Reason for Use code 665 For the treatment of adult patients with type 2 diabetes when adequate glycemic control is not achieved on the maximum tolerated dose of metformin or where metformin is contraindicated or inappropriate. Semaglutide is not funded in combination with another glucagon-like peptide-1 receptor agonist (GLP-1 RA) or dipeptidyl peptidase-4 (DPP-4) inhibitor. Injectable semaglutide is not funded in combination with oral semaglutide. Coverage is only provided for one dosage format. Reimbursed dose: As per the product monograph Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Semaglutide Injection · DIN 02568012 Manufacturer: Apotex Inc.; listing date 2026-06-30 Health Canada: Marketed since 2026-05-14 · brand APO-SEMAGLUTIDE INJECTION · ATC A10BJ06 SEMAGLUTIDE · form Solution · route Subcutaneous · ingredients SEMAGLUTIDE 1.34 MG/ML · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Semaglutide Injection: Formulary list price $78.14 per unit (the source does not state the unit; exact figure $78.1410). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02568012)

Source record
DIN 02568012: Apo-Semaglutide Injection Raw flags: insOH=Y, sec12=Y, sec3=Y Item: 682006001; group id 761; item number 1866; lccId 00384; manufacturer id APX Source form: Inj Sol-Pref Pen 3mL Pk; strength: 1.34mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; diabetes medication flag Source prices (unrounded): $78.1410; ministry $78.1410 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02568012 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=107037
Interchangeable products
Ozempic · DIN 02471469 · $78.1410 Semaglutide Injection · DIN 02567814 · $78.1410
Shortage status: active shortage (reported September 15, 2026, last updated September 17, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02568012
Shortage record checked October 6, 2026

Ozempic · DIN 02471469 · 1.34 mg/mL · injection solution-pre-filled pen 3mL Pk

Limited Use, Reason for Use code 665 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 665 required
Write on scriptReason for Use code 665 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 665
Reason for Use code 665 For the treatment of adult patients with type 2 diabetes when adequate glycemic control is not achieved on the maximum tolerated dose of metformin or where metformin is contraindicated or inappropriate. Semaglutide is not funded in combination with another glucagon-like peptide-1 receptor agonist (GLP-1 RA) or dipeptidyl peptidase-4 (DPP-4) inhibitor. Injectable semaglutide is not funded in combination with oral semaglutide. Coverage is only provided for one dosage format. Reimbursed dose: As per the product monograph Coverage limit: LU Authorization Period: Indefinite
Savings card: innoviCares lists Ozempic (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Ozempic · DIN 02471469 Manufacturer: Novo Nordisk Canada Inc; listing date 2019-09-30 Health Canada: Marketed since 2018-02-22 · brand OZEMPIC · ATC A10BJ06 SEMAGLUTIDE · form Solution · route Subcutaneous · ingredients SEMAGLUTIDE 1.34 MG/ML · company Novo nordisk canada inc · schedule Prescription, Schedule d
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02471469)

Source record
DIN 02471469: Ozempic Raw flags: insOH=Y, sec12=Y, sec3=Y Item: 682006001; group id 761; item number 1866; lccId 00384; manufacturer id NOO Source form: Inj Sol-Pref Pen 3mL Pk; strength: 1.34mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; diabetes medication flag Source prices (unrounded): $227.9400; ministry $78.1410 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02471469 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96058
Interchangeable products
Apo-Semaglutide Injection · DIN 02568012 · $78.1410 Semaglutide Injection · DIN 02567814 · $78.1410
Shortage status: resolved shortage (ended January 17, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02471469
Shortage record checked October 6, 2026

Semaglutide Injection · DIN 02567814 · 1.34 mg/mL · injection solution-pre-filled pen 3mL Pk

Limited Use, Reason for Use code 665 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 665 required
Write on scriptReason for Use code 665 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 665
Reason for Use code 665 For the treatment of adult patients with type 2 diabetes when adequate glycemic control is not achieved on the maximum tolerated dose of metformin or where metformin is contraindicated or inappropriate. Semaglutide is not funded in combination with another glucagon-like peptide-1 receptor agonist (GLP-1 RA) or dipeptidyl peptidase-4 (DPP-4) inhibitor. Injectable semaglutide is not funded in combination with oral semaglutide. Coverage is only provided for one dosage format. Reimbursed dose: As per the product monograph Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Semaglutide Injection · DIN 02567814 Manufacturer: Dr. Reddy's Laboratories Inc.; listing date 2026-06-30 Health Canada: Marketed since 2026-05-06 · brand SEMAGLUTIDE INJECTION · ATC A10BJ06 SEMAGLUTIDE · form Solution · route Subcutaneous · ingredients SEMAGLUTIDE 1.34 MG/ML · company Dr reddy's laboratories ltd · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Semaglutide Injection: Formulary list price $78.14 per unit (the source does not state the unit; exact figure $78.1410). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02567814)

Source record
DIN 02567814: Semaglutide Injection Raw flags: insOH=Y, sec12=Y, sec3=Y Item: 682006001; group id 761; item number 1866; lccId 00384; manufacturer id DRR Source form: Inj Sol-Pref Pen 3mL Pk; strength: 1.34mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; diabetes medication flag Source prices (unrounded): $78.1410; ministry $78.1410 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02567814 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=107019
Interchangeable products
Apo-Semaglutide Injection · DIN 02568012 · $78.1410 Ozempic · DIN 02471469 · $78.1410
Shortage status: active shortage (reported July 20, 2026, last updated September 16, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02567814
Shortage record checked October 6, 2026

Rybelsus · DIN 02551012 · 1.5 mg · tablet

Limited Use, Reason for Use code 738 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 738 required
Write on scriptReason for Use code 738 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 738
Reason for Use code 738 For the treatment of adult patients with type 2 diabetes when adequate glycemic control is not achieved on the maximum tolerated dose of metformin or where metformin is contraindicated or inappropriate. Semaglutide is not funded in combination with another glucagon like peptide-1 receptor agonist (GLP-1 RA) or dipeptidyl peptidase-4 (DPP-4) inhibitor. Oral semaglutide is not funded in combination with injectable semaglutide. Coverage is only provided for one dosage format. Maximum reimbursed dose: 1.5mg once daily. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Rybelsus · DIN 02551012 Manufacturer: Novo Nordisk Canada Inc; listing date 2026-03-31 Health Canada: Marketed since 2026-03-13 · brand RYBELSUS · ATC A10BJ06 SEMAGLUTIDE · form Tablet · route Oral · ingredients SEMAGLUTIDE 1.5 MG · company Novo nordisk canada inc · schedule Prescription, Schedule d
Re-check Health Canada status and shortages (live) · Health Canada product record

Rybelsus: Formulary list price $7.53 per unit (the source does not state the unit; exact figure $7.5303). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02551012)

Source record
DIN 02551012: Rybelsus Raw flags: insOH=Y, sec12=Y, sec3=Y Item: 682006010; group id 762; item number 1867; lccId 00428; manufacturer id NOO Source form: Tab; strength: 1.5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; diabetes medication flag Source prices (unrounded): $7.5303; ministry $7.5303 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02551012 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103977
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02551012
Shortage record checked October 6, 2026

Rybelsus · DIN 02497581 · 3 mg · tablet

Limited Use, Reason for Use code 662 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 662 required
Write on scriptReason for Use code 662 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 662
Reason for Use code 662 For the treatment of adult patients with type 2 diabetes when adequate glycemic control is not achieved on the maximum tolerated dose of metformin or where metformin is contraindicated or inappropriate. Semaglutide is not funded in combination with another glucagon like peptide-1 receptor agonist (GLP-1 RA) or dipeptidyl peptidase-4 (DPP-4) inhibitor. Oral semaglutide is not funded in combination with injectable semaglutide. Coverage is only provided for one dosage format. Maximum reimbursed dose: 3mg once daily. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Rybelsus · DIN 02497581 Manufacturer: Novo Nordisk Canada Inc; listing date 2023-12-29 Health Canada: Marketed since 2020-04-19 · brand RYBELSUS · ATC A10BJ06 SEMAGLUTIDE · form Tablet · route Oral · ingredients SEMAGLUTIDE 3 MG · company Novo nordisk canada inc · schedule Schedule d, Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Rybelsus: Formulary list price $7.53 per unit (the source does not state the unit; exact figure $7.5303). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02497581)

Source record
DIN 02497581: Rybelsus Raw flags: insOH=Y, sec12=Y, sec3=Y Item: 682006006; group id 763; item number 1868; lccId 00379; manufacturer id NOO Source form: Tab; strength: 3mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; diabetes medication flag Source prices (unrounded): $7.5303; ministry $7.5303 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02497581 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98740
Shortage status: anticipated shortage (last updated June 5, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02497581
Shortage record checked October 6, 2026

Rybelsus · DIN 02551020 · 4 mg · tablet

Limited Use, Reason for Use code 739 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 739 required
Write on scriptReason for Use code 739 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 739
Reason for Use code 739 For the treatment of adult patients with type 2 diabetes when adequate glycemic control is not achieved on the maximum tolerated dose of metformin or where metformin is contraindicated or inappropriate. Semaglutide is not funded in combination with another glucagon like peptide-1 receptor agonist (GLP-1 RA) or dipeptidyl peptidase-4 (DPP-4) inhibitor. Oral semaglutide is not funded in combination with injectable semaglutide. Coverage is only provided for one dosage format. Maximum reimbursed dose: 4mg once daily. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Rybelsus · DIN 02551020 Manufacturer: Novo Nordisk Canada Inc; listing date 2026-03-31 Health Canada: Marketed since 2026-03-13 · brand RYBELSUS · ATC A10BJ06 SEMAGLUTIDE · form Tablet · route Oral · ingredients SEMAGLUTIDE 4 MG · company Novo nordisk canada inc · schedule Prescription, Schedule d
Re-check Health Canada status and shortages (live) · Health Canada product record

Rybelsus: Formulary list price $7.53 per unit (the source does not state the unit; exact figure $7.5303). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02551020)

Source record
DIN 02551020: Rybelsus Raw flags: insOH=Y, sec12=Y, sec3=Y Item: 682006011; group id 764; item number 1869; lccId 00429; manufacturer id NOO Source form: Tab; strength: 4mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; diabetes medication flag Source prices (unrounded): $7.5303; ministry $7.5303 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02551020 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103978
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02551020
Shortage record checked October 6, 2026

Rybelsus · DIN 02497603 · 7 mg · tablet

Limited Use, Reason for Use code 663 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 663 required
Write on scriptReason for Use code 663 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 663
Reason for Use code 663 For the treatment of adult patients with type 2 diabetes when adequate glycemic control is not achieved on the maximum tolerated dose of metformin or where metformin is contraindicated or inappropriate. Semaglutide is not funded in combination with another glucagon like peptide-1 receptor agonist (GLP-1 RA) or dipeptidyl peptidase-4 (DPP-4) inhibitor. Oral semaglutide is not funded in combination with injectable semaglutide. Coverage is only provided for one dosage format. Maximum reimbursed dose: 7mg once daily. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Rybelsus · DIN 02497603 Manufacturer: Novo Nordisk Canada Inc; listing date 2023-12-29 Health Canada: Marketed since 2020-04-19 · brand RYBELSUS · ATC A10BJ06 SEMAGLUTIDE · form Tablet · route Oral · ingredients SEMAGLUTIDE 7 MG · company Novo nordisk canada inc · schedule Prescription, Schedule d
Re-check Health Canada status and shortages (live) · Health Canada product record

Rybelsus: Formulary list price $7.53 per unit (the source does not state the unit; exact figure $7.5303). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02497603)

Source record
DIN 02497603: Rybelsus Raw flags: insOH=Y, sec12=Y, sec3=Y Item: 682006007; group id 765; item number 1870; lccId 00380; manufacturer id NOO Source form: Tab; strength: 7mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; diabetes medication flag Source prices (unrounded): $7.5303; ministry $7.5303 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02497603 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98741
Shortage status: active shortage (reported June 18, 2026, last updated July 7, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02497603
Shortage record checked October 6, 2026

Rybelsus · DIN 02551039 · 9 mg · tablet

Limited Use, Reason for Use code 740 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 740 required
Write on scriptReason for Use code 740 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 740
Reason for Use code 740 For the treatment of adult patients with type 2 diabetes when adequate glycemic control is not achieved on the maximum tolerated dose of metformin or where metformin is contraindicated or inappropriate. Semaglutide is not funded in combination with another glucagon like peptide-1 receptor agonist (GLP-1 RA) or dipeptidyl peptidase-4 (DPP-4) inhibitor. Oral semaglutide is not funded in combination with injectable semaglutide. Coverage is only provided for one dosage format. Maximum reimbursed dose: 9mg once daily. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Rybelsus · DIN 02551039 Manufacturer: Novo Nordisk Canada Inc; listing date 2026-03-31 Health Canada: Marketed since 2026-03-13 · brand RYBELSUS · ATC A10BJ06 SEMAGLUTIDE · form Tablet · route Oral · ingredients SEMAGLUTIDE 9 MG · company Novo nordisk canada inc · schedule Schedule d, Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Rybelsus: Formulary list price $7.53 per unit (the source does not state the unit; exact figure $7.5303). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02551039)

Source record
DIN 02551039: Rybelsus Raw flags: insOH=Y, sec12=Y, sec3=Y Item: 682006012; group id 766; item number 1871; lccId 00430; manufacturer id NOO Source form: Tab; strength: 9mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; diabetes medication flag Source prices (unrounded): $7.5303; ministry $7.5303 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02551039 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103979
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02551039
Shortage record checked October 6, 2026

Rybelsus · DIN 02497611 · 14 mg · tablet

Limited Use, Reason for Use code 664 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 664 required
Write on scriptReason for Use code 664 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 664
Reason for Use code 664 For the treatment of adult patients with type 2 diabetes when adequate glycemic control is not achieved on the maximum tolerated dose of metformin or where metformin is contraindicated or inappropriate. Semaglutide is not funded in combination with another glucagon like peptide-1 receptor agonist (GLP-1 RA) or dipeptidyl peptidase-4 (DPP-4) inhibitor. Oral semaglutide is not funded in combination with injectable semaglutide. Coverage is only provided for one dosage format. Maximum reimbursed dose: 14mg once daily. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Rybelsus · DIN 02497611 Manufacturer: Novo Nordisk Canada Inc; listing date 2023-12-29 Health Canada: Marketed since 2020-04-19 · brand RYBELSUS · ATC A10BJ06 SEMAGLUTIDE · form Tablet · route Oral · ingredients SEMAGLUTIDE 14 MG · company Novo nordisk canada inc · schedule Schedule d, Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Rybelsus: Formulary list price $7.53 per unit (the source does not state the unit; exact figure $7.5303). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02497611)

Source record
DIN 02497611: Rybelsus Raw flags: insOH=Y, sec12=Y, sec3=Y Item: 682006008; group id 767; item number 1872; lccId 00381; manufacturer id NOO Source form: Tab; strength: 14mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; diabetes medication flag Source prices (unrounded): $7.5303; ministry $7.5303 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02497611 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98742
Shortage status: active shortage (reported June 2, 2026, last updated July 7, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02497611
Shortage record checked October 6, 2026

Wegovy · DIN 02528525 · 4 mg/3 mL · injection solution-3mL pre-filled pen

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 17, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
Savings card: innoviCares lists Wegovy (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Wegovy · DIN 02528525 Manufacturer: Novo Nordisk Canada Inc; listing date 2026-08-31 Health Canada: Marketed since 2024-03-28 · brand WEGOVY · ATC A10BJ06 SEMAGLUTIDE · form Solution · route Subcutaneous · ingredients SEMAGLUTIDE 4 MG/3ML · company Novo nordisk canada inc · schedule Prescription, Schedule d
Re-check Health Canada status and shortages (live) · Health Canada product record

Wegovy: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02528525)

Source record
DIN 02528525: Wegovy Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 920000822; group id 959; item number 2276; lccId None; manufacturer id NOO Source form: Inj Sol-3mL Pref Pen; strength: 4mg/3mL Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02528525 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101774
Interchangeable products
Sevmia · DIN 02569582 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02528525
Shortage record checked October 6, 2026

Ozempic · DIN 02471477 · 1.34 mg/mL · injection solution-pre-filled pen 1.5mL Pk

Limited Use, Reason for Use code 666 requiredDormant since July 24, 2026 · checked November 17, 2026 · What does dormant mean?
StatusLimited Use, Reason for Use code 666 required
Write on scriptReason for Use code 666 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 666
Reason for Use code 666 For the treatment of adult patients with type 2 diabetes when adequate glycemic control is not achieved on the maximum tolerated dose of metformin or where metformin is contraindicated or inappropriate. Semaglutide is not funded in combination with another glucagon-like peptide-1 receptor agonist (GLP-1 RA) or dipeptidyl peptidase-4 (DPP-4) inhibitor. Injectable semaglutide is not funded in combination with oral semaglutide. Coverage is only provided for one dosage format. Reimbursed dose: As per the product monograph Coverage limit: LU Authorization Period: Indefinite
Savings card: innoviCares lists Ozempic (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Ozempic · DIN 02471477 Manufacturer: Novo Nordisk Canada Inc; listing date 2019-09-30 Health Canada: Dormant since 2026-07-24 · brand OZEMPIC · ATC A10BJ06 SEMAGLUTIDE · form Solution · route Subcutaneous · ingredients SEMAGLUTIDE 1.34 MG/ML · company Novo nordisk canada inc · schedule Schedule d, Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02471477)

Source record
DIN 02471477: Ozempic Raw flags: insOH=Y, sec12=Y, sec3=Y Item: 682006002; group id 760; item number 1865; lccId 00383; manufacturer id NOO Source form: Inj Sol-Pref Pen 1.5mL Pk; strength: 1.34mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; diabetes medication flag Source prices (unrounded): $227.9400; ministry $78.1410 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02471477 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96059
Interchangeable products
Semaglutide Injection · DIN 02567806 · $78.1410
Shortage status: resolved shortage (ended February 16, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02471477
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since July 24, 2026 — choose a marketed DIN from the same-category list.

Sevmia · DIN 02569582 · 4 mg/3 mL · injection solution-3mL pre-filled pen

Off-Formulary Interchangeable, not an ODB benefitApproved · checked November 17, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Sevmia · DIN 02569582 Manufacturer: Apotex Inc.; listing date 2026-08-31 Health Canada: Approved since 2026-06-29 · brand SEVMIA · ATC A10BJ06 SEMAGLUTIDE · form Solution · route Subcutaneous · ingredients SEMAGLUTIDE 4 MG/3ML · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02569582)

Source record
DIN 02569582: Sevmia Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 920000822; group id 959; item number 2276; lccId None; manufacturer id APX Source form: Inj Sol-3mL Pref Pen; strength: 4mg/3mL Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $325.0480; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02569582 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=107181
Interchangeable products
Wegovy · DIN 02528525 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02569582
Shortage record checked October 6, 2026
Health Canada lists this DIN as Approved since June 29, 2026 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary classes and how they are covered

Other drugs in the same formulary class (68:20:06 Incretin Mimetics) and how they are covered

Matched class: 68:20:06 Incretin Mimetics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: INSULIN GLARGINE & LIXISENATIDE 68:20:06 Incretin Mimetics

INSULIN GLARGINE & LIXISENATIDE

· 1 products · General benefit · strengths: 100U/mL & 33mcg/mL · Inj Sol-Pref Pen 5x3mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 68:20:06
Full class listing Related classes: 68:20:02 Oral Anti-Diabetic Agents, 68:20:10 Insulins (Rapid Acting), 68:20:12 Insulins (Intermediate Acting), 68:20:14 Insulins (Long Acting), 68:20:16 Insulins (Pre-Mixed)

Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM, RISPERIDONE Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab

CYCLOSPORINE

· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L

GLUCAGON RDNA ORIGIN

· 2 products · General benefit · strengths: 1mg/Vial · Inj Pd-Syr Pk, Inj Pd-Vial Pk

LANREOTIDE ACETATE

· 6 products · General benefit · strengths: 60mg/Syr, 90mg/Syr, 120mg/Syr · ER Pref Syr Pk

LEFLUNOMIDE

· 16 products · General benefit · strengths: 10mg, 20mg · Tab

LEVODOPA & BENSERAZIDE

· 3 products · General benefit · strengths: 50mg & 12.5mg, 100mg & 25mg, 200mg & 50mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 92:00 and 78 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: major adverse cardiovascular events, type 2 diabetes
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: CANAGLIFLOZIN ACARBOSE · Listed, not a benefit (2), Limited Use, codes 175, 176 (2) INDICATIONS AND CLINICAL USE • MAR-ACARBOSE (acarbose), as monotherapy, is indicated as an adjunct to prescribed diet for the management of blood glucose levels in patients with type 2 diabetes mellitus who are inadequately controlled by diet alone. PM: https://pdf.hres.ca/dpd_pm/00053914.PDF; date not captured; DIN 02494078; fetched 2026-09-10 Product monograph CANAGLIFLOZIN · General benefit Add-On Combination in Patients with Established Cardiovascular Disease: INVOKANA is indicated as an adjunct to diet, exercise, and standard of care therapy to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction and nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease (CVD). PM: https://pdf.hres.ca/dpd_pm/00074895.PDF; date May 22, 2014; DIN 02425483; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
1. Indications OZEMPIC® is indicated for the once-weekly treatment of adult patients with type 2 diabetes to improve glycemic control, in combination with: • diet and exercise in patients for whom metformin is inappropriate due to contraindication or intolerance. • metformin, when diet and exercise plus maximal tolerated dose of metformin do not achieve adequate glycemic control. • metformin and a sulfonylurea, when diet and exercise plus dual therapy with metformin and a sulfonylurea do not achieve adequate glycemic control. • metformin or a sulfonylurea and a sodium-glucose cotransporter 2 inhibitor (SGLT2i), when diet and exercise plus metformin or a sulfonylurea, in addition to an SGLT2i, do not achieve adequate glycemic control. • basal insulin with metformin, when diet and exercise plus basal insulin with metformin do not achieve adequate glycemic control (see 14 Clinical Trials). OZEMPIC® is indicated as an adjunct to diet, exercise, and standard of care to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, … https://pdf.hres.ca/dpd_pm/00085314.PDF PM date: 2026-07-13 Source product: OZEMPIC; DIN 02471469; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Apo-Semaglutide Injection · DIN 02568020 Shortage status: active shortage (reported 2026-09-15, last updated 2026-09-17); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02568020

Check this DIN again

Semaglutide Injection · DIN 02567806 Shortage status: active shortage (reported 2026-07-20, last updated 2026-09-16); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02567806

Check this DIN again

Apo-Semaglutide Injection · DIN 02568012 Shortage status: active shortage (reported 2026-09-15, last updated 2026-09-17); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02568012

Check this DIN again

Semaglutide Injection · DIN 02567814 Shortage status: active shortage (reported 2026-07-20, last updated 2026-09-16); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02567814

Check this DIN again

Rybelsus · DIN 02497603 Shortage status: active shortage (reported 2026-06-18, last updated 2026-07-07); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02497603

Check this DIN again

Rybelsus · DIN 02497611 Shortage status: active shortage (reported 2026-06-02, last updated 2026-07-07); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02497611

Check this DIN again
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, September 10, 2026 ↗)

Other review policies

For Wegovy, Sevmia: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026